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Combination of RAD001 
(everolimus) and docetaxel reduces 
prostate and breast cancer cell 
VEGF production and tumour 
vascularisation independently of 
sphingosine-kinase-1
Heba Alshaker1,2, Qi Wang1, Torsten Böhler3, Robert Mills4, Mathias Winkler3, Tawfiq Arafat2, 
Yoshiaki Kawano5 & Dmitri Pchejetski1
Resistance to docetaxel is a key problem in current prostate and breast cancer management. We 
have recently discovered a new molecular mechanism of prostate cancer docetaxel chemoresistance 
mediated by the mammalian target of rapamycin (mTOR)/sphingosine-kinase-1 (SK1) pathway. 
Here we investigated the influence of this pathway on vascular endothelial growth factor (VEGF) 
production and tumour vascularisation in hormone resistant prostate and breast cancer models. 
Immunofluorescent staining of tumour sections from human oestrogen receptor (ER)-negative 
breast cancer patients showed a strong correlation between phosphorylated P70S6 kinase (mTOR 
downstream target), VEGF and SK1 protein expression. In hormone-insensitive prostate (PC3) and 
breast (MDA-MB-231 and BT-549) cancer cell lines the mTOR inhibitor RAD001 (everolimus) has 
significantly inhibited SK1 and VEGF expression, while low dose (5 nM) docetaxel had no significant 
effect. In these cell lines, SK1 overexpression slightly increased the basal levels of VEGF, but did not 
block the inhibitory effect of RAD001 on VEGF. In a human prostate xenograft model established in 
nude mice, RAD001 alone or in combination with docetaxel has suppressed tumour growth, VEGF 
expression and decreased tumour vasculature. Overall, our data demonstrate a new mechanism of an 
independent regulation of SK1 and VEGF by mTOR in hormone-insensitive prostate and breast cancers.
Docetaxel is an antineoplastic taxane that is widely used for the treatment and management of patients with 
breast1 and prostate cancers2. Docetaxel acts by disrupting microtubule disassembly, resulting in inhibition of 
mitosis, and ultimately leading to apoptosis2. However, drug-related cumulative toxicity, unresponsiveness to 
docetaxel therapy, and the development of resistance limit its clinical benefits3–5. Many tumour cells express vas-
cular endothelial growth factor (VEGF) as a principal regulator of angiogenesis. VEGF induces proliferation of 
endothelial cells, primarily via the VEGF receptor 2, which in turn increases neovascularisation6. Combinations 
of docetaxel with antiangiogenic compounds such as bevacizumab (anti-VEGF recombinant humanised mono-
clonal antibody), provide clinical benefit in the treatment of metastatic breast and prostate cancers7.
Mammalian target of rapamycin (mTOR) is a protein kinase that is present in two distinct complexes: mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2)8. The mTORC1 plays a central role in regulating critical 
cellular processes and deregulation of the mTORC1 signalling pathway is closely associated with tumourigene-
sis8, 9. In breast tumours, mTORC1 also controls angiogenic pathways via VEGF10, therefore, mTOR represents 
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a validated target for the treatment of cancer. There is increasing clinical evidence showing promising activ-
ity of mTOR inhibitors (rapalogues) against solid tumors and hematologic malignancies9. One such rapalogue, 
RAD001 (everolimus), is an inhibitor of mTORC1 with limited or no effect on mTORC2 activity11. RAD001 
forms a complex with the intracellular receptor FK506 binding protein 12, which interferes with mTOR activ-
ity preventing downstream signalling9. Cellular effects of RAD001 include enhancement of apoptosis in some 
tumour cell lines as well as inhibition of cell proliferation, migration, and angiogenesis in some human cancers11. 
RAD001 is approved for treatment of metastatic renal-cell carcinoma12, pancreatic neuroendocrine tumours, and 
some subtypes of breast cancer11.
Increased expression of lipid kinase, sphingosine-kinase-1 (SK1), contributes to cancer progression and onco-
genic transformation13. Sustained SK1 expression was linked to prostate cancer chemoresistance to low dose 
taxanes14. Breast tumours from patients with locally advanced or metastatic cancers with docetaxel-based chemo-
therapy had significantly higher SK1 mRNA levels in patients who were non-responders to treatment compared 
to complete or partial responders15. In a previous study, we revealed that RAD001 sensitizes PC3 and DU145 
prostate cancer cells and tumours to docetaxel therapy through downregulation of mTOR/SK1 pathway16. In 
breast cancer cells, mTOR inhibition by temsirolimus inhibited angiogenesis via transcriptional inhibition of 
VEGF production10. Here we have investigated the effects of docetaxel/RAD001 combination therapy on VEGF 
regulation in hormone insensitive prostate and breast cancer cells. Our data from primary human breast tumours 
and human prostate cancer animal models have shown a correlated expression of SK1 and VEGF, which suggests 
a common regulatory mechanism. Indeed, in PC3, DU145, MDA-MB-231 and BT-549 cancer cells RAD001 
downregulated both SK1 and VEGF through mTOR inhibition. However, contrary to chemoresistance that was 
shown in PC3 and DU145 cells16, SK1 overexpression did not abrogate RAD001-induced reduction in VEGF 
in prostate (PC3) and breast (MDA-MB-231) cancer models, suggesting that the two pathways are regulated 
independently. In vivo, RAD001-induced VEGF downregulation has significantly decreased prostate tumour vas-
cularisation and acted in synergy with docetaxel to reduce prostate tumour growth. Overall, our results provide 
novel insights into the mechanisms of synergistic RAD001/docetaxel combination and highlight the potential for 
the use of this combined therapy in hormone-insensitive prostate and breast cancers.
Results
In breast cancer patients VEGF and SK1 protein expression correlate to phosphorylated 
(p)-P70S6 Kinase (P70S6K) levels. To delineate the correlation of the investigated pathways in human 
patients we used immunofluorescence to quantify relative P70S6K phosphorylation, SK1 and VEGF expression 
in paraffinised sections of human oestrogen receptor (ER)-negative breast tumours. There was a strong positive 
correlation between p-P70S6K and VEGF, p-P70S6K and SK1, but less so between SK1 and VEGF (p < 0.001, 
R = 0.61), (p < 0.001, R = 0.72) and (p < 0.05, R = 0.42), respectively (Fig. 1).
RAD001 but not docetaxel decreases SK1 and VEGF expression in MDA-MB-231 and PC3 
cells. To elucidate the mechanisms implicated in the effects of RAD001 in combination with docetaxel, we 
first analysed the effect of docetaxel on the expression of SK1 in MDA-MB-231. Similar to the previous find-
ings in PC3 and DU145 prostate cancer cells16, docetaxel did not decrease the levels of P70S6K phosphoryla-
tion (a marker for mTOR activity), SK1 mRNA or activity, but rather insignificantly increased them (Fig. 2). In 
contrast, RAD001 alone or in combination with docetaxel has significantly decreased P70S6K phosphorylation, 
SK1 mRNA and activity in ER-negative MDA-MB-231 and BT-549 breast cancer cells (Figs 2, S1) and hormone 
refractory prostate cancer cells PC3 (Fig. 2). We have previously shown a similar effect of RAD001 on SK1 activity 
and expression in another hormone refractory prostate cancer cell line DU14516. In MDA-MB-231 breast cancer 
cells p-P70S6K ELISA findings were confirmed using Western blotting (Figure S2). In PC3 and DU145 prostate 
cancer cells, we have previously shown that Western blotting and ELISA show similar results16.
mTOR regulation of VEGF was suggested in human epidermal growth factor receptor 2 (HER2) positive 
breast cancer in response to activation of ERB2/PI3K/Akt pathway17. Similarly, in prostate cancer, mTOR inhi-
bition with rapamycin was shown to inhibit VEGF secretion18, however the combined effects of RAD001 and 
docetaxel on prostate cancer VEGF production were never studied. Here we show for the first time that in 
MDA-MB-231, BT-549 and PC3 cells, 5 nM docetaxel increased VEGF mRNA, but did not change secreted VEGF 
levels (Figs 3, S3). RAD001 alone or in combination with docetaxel significantly decreased both VEGF mRNA 
levels and VEGF secretion (Figs 3, S3).
SK1 overexpression increases basal P70S6K phosphorylation and VEGF expression. We have 
recently shown that in PC3 and DU145 prostate cancer cells mTOR-mediated SK1 expression plays a key role in 
cancer cell chemoresistance16. Previously SK1/sphingosine-1-phosphate (S1P) signalling was implicated in breast 
cancer angiogenesis and lymphangiogenesis19, but the direct link with VEGF was never demonstrated.
To study the effect of SK1 on VEGF production we used MDA-MB-231 cells overexpressing SK1 (MDA/
SK1) that had 14- and 11-fold increase in SK1 expression and activity, respectively, in comparison to empty 
vector-transfected cells (MDA/Neo) (Fig. 4). SK1 overexpression has led to a 40% increase in P70S6K phospho-
rylation, 37% increase in VEGF expression and 48% increase in VEGF secretion (Figs 4, S4). Similar findings 
were observed in PC3 prostate cancer cells overexpressing SK1 (Fig. 4). These cells had a 55%, 30% and 31% 
increase in P70S6K phosphorylation, VEGF expression and VEGF secretion, respectively, in comparison to their 
empty vector transfected counterparts (Fig. 4). Of note, empty vector transfection did not alter SK1 activity, 
expression, P70S6K phosphorylation, VEGF expression and secretion in comparison to wild-type cells.
SK1 overexpression does not affect RAD001-induced VEGF downregulation. We have next 
investigated the effect of RAD001/docetaxel combination on empty vector- and SK1-overexpressing PC3 and 
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Figure 1. In oestrogen receptor (ER)-negative human breast tumours P70S6K phosphorylation correlates 
with SK1 and VEGF expression. Human breast tumours (n = 30) were stained with anti-SK1, anti-VEGF and 
anti-p-P70S6K antibodies. Tumour sections were immunostained as described in materials and methods 
and fluorescence was visualised using Zeiss Axioplan microscope and quantified using ImageJ software. (A) 
Representative immunofluorescence images of two different tumour sections. Correlation between VEGF and 
p-P70S6K (B) SK1 and p-P70S6K (C) and SK1 and VEGF (D) in FFPE human ER-negative breast tumours.
Figure 2. RAD001 but not docetaxel decreases SK1 expression in MDA-MB-231 and PC3 cells. MDA-MB-231 
and PC3 cells were starved overnight then incubated with 0.1% DMSO (Cont), 100 nM RAD001 (RAD), 5 nM 
docetaxel (Doc) and the combination of these drugs (RAD + Doc) for 24 h. (A,D) P70S6K phosphorylation was 
measured using ELISA. (B,E) SK1 expression was determined by qRT-PCR. (C,F) SK1 activity was measured 
using radiolabelling. Columns, mean of three independent experiments performed in triplicate; bars, SEM. 
(*P < 0.05; **P < 0.01; §P < 0.001; ns, not significant, P > 0.05).
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MDA-MB-231 cancer cells. MDA/SK1 cells treated with RAD001 alone or in combination with docetaxel showed 
similar relative reduction in p-P70S6K levels to MDA/Neo cells, which correlated to same levels of relative reduc-
tion in VEGF levels (Figs 5, S4). Similar findings were observed in PC3/SK1 and PC3/Neo cells (Fig. 5).
Combination of RAD001 and docetaxel blocks prostate tumour growth and decreases tumour 
vasculature. BALB/c nude mice were subcutaneously implanted with 106 PC3 cells and tumours were left to 
grow for two weeks. Mice were randomized into groups and treated twice a week with sham intraperitoneal injec-
tions, 5 mg/kg docetaxel, 5 mg/kg RAD001 or combination of these drugs for three weeks. As shown in Fig. 6A, 
treatment with RAD001 has significantly sensitised prostate tumours to small and otherwise inefficient doses of 
docetaxel achieving a staggering 58% tumour volume reduction in comparison to 23% and 15% by individual 
RAD001 and docetaxel therapies, respectively (Figs 6A,B, S5). ELISA and qRT-PCR analysis demonstrated that 
both RAD001 and combined therapy have significantly downregulated tumour p-P70S6K (Fig. 6C), SK1, VEGF 
and CD31 expression (Fig. 6D–F).
Discussion
In our recent publication, we have identified a new mechanism of RAD001-induced sensitisation to docetaxel 
therapy in prostate cancer16. We have found that mTOR controls the expression of a proto-oncogene SK1, which 
in turn mediates chemoresistance. We have shown that combining RAD001 with low dose docetaxel suppresses 
SK1 activity and acts in synergy in human prostate cancer mouse model drastically reducing tumour size16.
The mTOR signalling has high clinical relevance in human prostate and breast cancers. In prostate cancer 
patients, there was a statistically significant decrease of mTOR and PS6K expression after hormonal deprivation 
therapy20. High expression of nuclear phosphorylated mTOR in ER-negative breast carcinomas suggests that 
mTOR inhibitors may be effective in at least some patients with this subtype of breast cancer21. Previously we 
reported that SK1 expression was significantly higher in lymph nodes derived from ER-negative breast tumours 
when compared to ER-positive22, 23. Our previous findings were corroborated by a recent report15 showing that 
ER-negative breast tumours express higher SK1 mRNA compared to ER-positive tumours, which correlate with 
poor overall and progression-free survival in breast cancer patients. Additionally, higher SK1 mRNA levels were 
observed in breast cancer patients who were non-responders to docetaxel treatment compared to complete or 
Figure 3. RAD001 but not docetaxel decreases VEGF expression in MDA-MB-231 and PC3 cells. 
MDA-MB-231 and PC3 cells were starved overnight then incubated with 0.1% DMSO (Cont), 100 nM 
RAD001 (RAD), 5 nM docetaxel (Doc) and the combination of these drugs (RAD + Doc) for 24 h. (A,C) VEGF 
expression was determined by qRT-PCR (B,D) VEGF protein levels were measured using ELISA. Columns, 
mean of three independent experiments performed in triplicate; bars, SEM. (*P < 0.05; **P < 0.01; §P < 0.001; ns, 
not significant, P > 0.05).
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partial responders15. Immunofluorescent analysis of ER-negative breast tumours shows a strong positive cor-
relation between p-P70S6K/VEGF and p-P70S6K/SK1 and albeit smaller correlation between SK1 and VEGF 
(Fig. 1).
Here we show that similar to hormone refractory prostate cancer cells PC3 and DU14516, in ER-negative 
breast cancer cells MDA-MB-231 and BT-549 RAD001 alone or in combination with docetaxel, but not docetaxel 
alone, can downregulate p-P70S6K and SK1 signalling (Figs 2, S1), suggesting the presence of a similar pathway 
in breast cancer. A wealth of evidence suggests an important role for the mTOR/VEGF pathway in HER2 positive 
Figure 4. Overexpression of SK1 increases basal P70S6K phosphorylation and VEGF expression. Cell extracts 
for wild type MDA-MB-231 (MDA/WT) and PC3 (PC3/WT), empty vector-transfected MDA-MB-231 
(MDA/Neo) and PC3 cells (PC3/Neo) and MDA-MB-231 and PC3 cells stably transfected with human SK1 
(MDA/SK1 and PC3/SK1, respectively) were collected. (A,F) P70S6K phosphorylation was measured using 
ELISA. (B,G) SK1 expression and VEGF expression (D,I) was determined by qRT-PCR. (C,H) SK1 activity 
was measured using radiolabelling. (E,J) VEGF protein levels were measured using ELISA. Columns, mean of 
three independent experiments performed in triplicate; bars, SEM. (*P < 0.05; **P < 0.01; §P < 0.001; ns, not 
significant, P > 0.05).
Figure 5. SK1 overexpression does not affect RAD001-induced VEGF downregulation. Wild type, empty 
vector- and SK1-overexpressing MDA-MB-231 and PC3 cells were starved overnight then incubated with 
0.1% DMSO (Control), 100 nM RAD001 (RAD), 5 nM docetaxel (Doc) and the combination of these drugs 
(RAD + Doc) for 24 h. (A,D) P70S6K phosphorylation was measured using ELISA. (B,E) VEGF expression 
was determined by qRT-PCR. (C,F) VEGF protein levels were measured using ELISA. Columns, mean of 
three independent experiments performed in triplicate expressed as relative to control; bars, SEM. (*P < 0.05; 
**P < 0.01; §P < 0.001; ns, not significant, P > 0.05).
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breast cancer after the initial finding that rapamycin can dramatically inhibit breast tumour growth and vascular-
isation17. In the HER2 gene-amplified breast cancer cells, temsirolimus inhibited VEGF production in vitro under 
both normoxic and hypoxic conditions10. Authors observed a similar effect in MDA-MB-231 cells10. Similarly, in 
PC3 prostate cancer cells RAD001 reduced the secretion of VEGF24. Interestingly, in one publication authors have 
shown that docetaxel increases VEGF expression in breast and prostate cancer cells7. This provides rationale for 
the use of anti-VEGF therapy together with docetaxel in these cancers. In this context, RAD001/docetaxel com-
bination was previously tested in ER-negative breast cancer stem cells25, but its effect on VEGF-mediated tumour 
vascularisation was not elucidated. Here we show that in both cell lines, docetaxel has increased VEGF mRNA 
levels, but did not change the levels of secreted protein, while RAD001 alone or in combination with docetaxel 
significantly decreased these levels (Fig. 3).
We have previously shown that increased SK1 expression is observed in aggressive human prostate tumours26, 27  
and ER-negative breast cancers22, 23. There is a significant link between SK1 and angiogenesis, however, most stud-
ies agree that the mechanism is VEGF-independent and is mediated by SK1-produced S1P and its extracellular 
receptors13. One publication has shown that S1P produced by SK1 increases the level of VEGF mRNA in human 
umbilical vein endothelial cells (HUVECs)28, however in breast cancer cells SK1/S1P activation was sufficient to 
induce angiogenesis without the involvement of VEGF pathway19. Our data suggest that while in both PC3 and 
MDA-MB-231 cancer cells SK1 overexpression slightly increases basal VEGF levels (Fig. 4), it does not affect 
RAD001-induced VEGF reduction (Fig. 5).
Since the initial hallmark paper demonstrating the ability of rapamycin to downregulate tumour VEGF lev-
els29, the ability of mTOR inhibitors to elicit antiangiogenic effects by downregulation of VEGF, made them key 
candidates for the investigation of new combined chemotherapy regimens. RAD001 was shown to have an addi-
tive effect to docetaxel in reducing the volumes of the xenograft tumours induced in mice by MDA-MB-231 
stem cells25. Similarly, we have recently shown that combined RAD001 and docetaxel treatment had synergy in 
reducing PC3 tumour growth in nude mice16. However, in neither system VEGF expression was studied. Here we 
evaluated the effect of RAD001 alone or in combination with docetaxel on prostate tumour VEGF production 
and tumour vascularisation. Treatment with RAD001 has significantly sensitised PC3 prostate tumours to small 
and otherwise inefficient doses of docetaxel achieving a staggering 58% tumour volume reduction in comparison 
to 23% and 15% by individual RAD001 and docetaxel therapies, respectively (Figs 6, S5). All therapies containing 
RAD001 have significantly downregulated tumour p-P70S6K levels, SK1, VEGF and CD31 expression (Fig. 6). 
In ER-negative breast tumours, p-P70S6K/VEGF and p-P70S6K/SK1 have exhibited high degree of correlation, 
however, SK1/VEGF had a lower degree of correlation, suggesting the absence of cross-regulation (Fig. 1).
In conclusion, we show that both in prostate and breast cancers VEGF and SK1 are independently regulated by 
mTORC1. mTOR inhibition significantly reduces VEGF and tumour vascularisation and complements docetaxel 
therapy. Our data provide rationale for potential use of mTOR inhibitors in combination with docetaxel in these 
cancers.
Figure 6. RAD001 decreases tumour vasculature in mouse model of human prostate cancer. Subcutaneous 
PC3 tumours were established in nude mice as described in materials and methods and allowed to grow 
for two weeks. Mice were treated with sham (Cont), 5 mg/kg RAD001 (RAD), 5 mg/kg docetaxel (Doc) 
and combination of these drugs (RAD + Doc) for three weeks. (A) Representative images of subcutaneous 
human tumours in mice after corresponding treatments. (B) Tumour volumes at week five. (C) P70S6K 
phosphorylation in tumours was measured using ELISA. (D–F) Human SK1 (D), VEGF (E) and mouse CD31 
(F) expression was determined by qRT-PCR. Columns, mean values of n = 8; bars, SEM. (*P < 0.05; **P < 0.01; 
§P < 0.001; ns, not significant, P > 0.05).
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Methods
Patients’ samples. Archival paraffin-embedded tissue from 30 patients with ER-negative primary breast 
tumours was obtained from Imperial College NHS Trust tissue bank. Prior to donating their samples to the bank, 
all patients filled an informed consent for their subsequent use in research projects and publications. The study 
was approved by National Research Ethics Service and performed in accordance with ethical guidelines. None of 
the patients received neo-adjuvant therapy. Clinicopathological details of the patients enrolled in this study are 
listed in Table S1. All samples were formalin-fixed and paraffin-embedded (FFPE). Four sections (5-µm-thick) 
were macro dissected from the FFPE blocks with trimming of excess paraffin. Only tissue containing at least 70% 
of tumour was used for immunofluorescence.
Cell lines and cell culture. Androgen insensitive prostate cancer cell line (PC3) was obtained from DSMZ 
(Braunschweig, Germany). Breast cancer cell lines MDA-MB-231 and BT-549 were purchased from ATCC 
(Manassas, VA, USA). PC3/SK1 and MDA/SK1 were derived from parental cell lines through stable transfection 
with human SK116, 30–33. Cells were maintained in tissue culture flasks or plastic dishes in a humidified atmosphere 
of 5% CO2 at 37 °C using Roswell Park Memorial Institute (RPMI) 1640 for PC3 or Dulbecco’s Modified Eagle’s 
Medium (DMEM) for MDA-MB-231 and BT-549 supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (Sigma‐Aldrich, UK), 50 U/ml penicillin, 50 μg/ml streptomycin and 2 mM glutamine (Sigma‐Aldrich, 
UK). In the case of stably transfected cancer cell lines, the growth medium was supplemented with 1 mg/ml 
Geneticin sulfate (G418, Santa Cruz Biotechnology, Heidelberg, Germany). Cell lines were routinely verified 
by morphology and growth curve analysis and routinely screened for mycoplasma infection (using MP0035 
Lookout, Sigma). All experiments were conducted in the absence of serum. Cells were seeded to be 80% conflu-
ent by the end of the treatment and were treated as indicated in figures’ legends. Cell lines were kept in culture for 
up to 30 passages.
Reagents. Silica gel 60 high-performance TLC plates were from VWR (West Chester, PA, USA), and 
[γ-32P]-ATP was purchased from Perkin-Elmer (Waltham, MA, USA). RAD001 (everolimus) from Selleckchem 
(Newmarket, UK). Other reagents and chemicals used were purchased from Sigma-Aldrich (Dorset, UK) unless 
otherwise specified.
ELISA for p-P70S6K (Thr389). For the measurements of p-P70S6K, cancer cell or tumour lysates were 
prepared and ELISA was conducted as previously described16. Equal amount of lysates was loaded onto PathScan 
p-P70S6K plates and PathScan total P70S6K plates (Cell Signaling, Danvers, USA), and the assay was performed 
according to manufacturer’s instructions. Levels of p-P70S6K were normalized to corresponding total P70S6K 
levels.
RNA extraction, cDNA synthesis and qRT-PCR. Isolation of total RNA from prostate cancer cell lines 
and mouse tumours was performed using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) as per manufactur-
er’s instructions. RNA quantity and purity was measured using a NanoDrop 2000c Spectrophotometer (Thermo 
Fisher Scientific, Loughborough, UK). Reverse transcription was performed using Precision nanoScript™ 
Reverse transcription kit (PrimerDesign Ltd, Southampton, UK). qRT-PCR was done as previously described22, 23. 
Ct values were exported and analysed using qbase software (Biogazelle NV, Zwijnaarde, Belgium).
Sphingosine kinase 1 assay. SK1 assay was performed using radiolabelling as previously described23, 34, in 
conditions favouring SK1 activity and inhibiting SK2 activity.
Animal study. Animal study was performed as previously described16, 31, 33. Briefly, subcutaneous human 
prostate cancer xenografts were established in BALB/c nude male mice by subcutaneous injection of 1*106 PC3 
cells. Two weeks after implantation, mice were randomized into treatment groups and treated twice a week for 
three weeks with: i.p. injections of vehicle (control), 5 mg/kg docetaxel, 5 mg/kg RAD001 and a combination of 
these drugs. One day after the last treatment, all mice were euthanized. Mice primary tumours were frozen and 
processed for radiolabelling, ELISA and qRT-PCR analysis. Animal studies were performed under the Home 
Office license and carried out in in accordance with the institutional guidelines and regulations for animal welfare 
(University of East Anglia) and NC3Rs (Replacement, Reduction and Refinement) guidelines. The experiments 
were carried out in accordance to the protocols section 19B of the Home Office licence and were approved by the 
University of East Anglia animal welfare committee.
Immunofluorescent staining of human tumours. Fluorescent immunostaining was performed using 
5-µm-thick FFPE tissues of human ER-negative primary breast tumours. Tissues were deparaffinised in xylene 
and were rehydrated in graded ethanol (100, 95, 80, 70, 50 and 30% v/v). Antigen retrieval was performed by 
incubation with 20 µg/ml Proteinase K for 30 min at 37 °C. Sections were incubated in blocking buffer (5% v/v 
normal donkey serum in PBS) for 2 h at room temperature then probed with antibodies against SK1, VEGF 
(Abcam, UK) and p-P70S6K (Thr389) (SantaCruz Biotechnology, UK) overnight in a humidified chamber at 
4 °C. Slides were washed in 0.1% Tween-20 in PBS (pH 7.2–7.4) and were incubated with secondary Alexa Fluor 
488-conjugated anti-rabbit IgG, (Abcam, UK), and Alexa Fluor 647-conjugated anti-goat IgG (ThermoFisher 
Scientific, UK), for 2 h at room temperature. Cell nuclei were counterstained using DAPI, and fluorescence was 
visualised using Zeiss Axioplan immuno fluorescent microscope. Image analysis was performed using the ImageJ 
software (http://rsb.info.nih.gov/ij) and the threshold was set according to the negative control captured image.
Statistical analysis. Data are presented as the mean values of at least three independent experiments nor-
malised to control ± standard error of the mean (SEM) calculated using GraphPad Prism. Statistical significance 
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between two groups was conducted by unpaired Student’s t test. Comparisons between the means of more than 
two groups were assessed using one-way ANOVA analysis followed by a Tukey’s test (95% confidence). P value 
of < 0.05 is considered statistically significant. The Pearson’s correlation coefficient was calculated between the 
expression levels of two target genes.
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